<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe the incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in patients with primary <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> disorders (PIDD) following hematopoietic cell transplantation (HCT) </plain></SENT>
<SENT sid="1" pm="."><plain>From the Center for International Blood and Marrow Transplant Research, 2266 PIDD patients who had undergone allogeneic HCT between 1968 and 2003 were identified </plain></SENT>
<SENT sid="2" pm="."><plain>Patient, disease, and transplant factors for development of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> were examined and pathology reports for reported <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> reviewed independently by a pathologist for confirmation </plain></SENT>
<SENT sid="3" pm="."><plain>The incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> was highest for <z:e sem="disease" ids="C0043194" disease_type="Disease or Syndrome" abbrv="">Wiskott-Aldrich syndrome</z:e> (3.3%), with an overall incidence of 2.3% for PIDD </plain></SENT>
<SENT sid="4" pm="."><plain>Post-HCT <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> was confirmed for 52 of 63 reported cases </plain></SENT>
<SENT sid="5" pm="."><plain>Forty-five of 52 patients developed posttransplant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (PTLD) at a median of 3 months post-HCT </plain></SENT>
<SENT sid="6" pm="."><plain>Of these, 26 had received T cell-depleted (TCD) bone marrow </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients who developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> had received TCD marrow and total body irradiation </plain></SENT>
<SENT sid="8" pm="."><plain>Three patients developed a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with PIDD are at a relatively low risk of developing <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> post-HCT compared with their historic risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>The most frequent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> or <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> was early-<z:hpo ids='HP_0003674'>onset</z:hpo> PTLD </plain></SENT>
<SENT sid="11" pm="."><plain>As in other HCT recipients, TCD appears to correlate with PTLD development </plain></SENT>
<SENT sid="12" pm="."><plain>Our results lend support to the hypothesis that immune reconstitution in PIDD following HCT leads to a decrease in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
</text></document>